When should C‑peptide be measured after a hyperglycemic crisis?

When to Test C-Peptide After Hyperglycemic Crisis

Do not test C-peptide within 2 weeks of a hyperglycemic emergency. 1, 2

Rationale for the 2-Week Waiting Period

The American Diabetes Association explicitly states that C-peptide testing should be avoided within 2 weeks following a hyperglycemic crisis (diabetic ketoacidosis or hyperosmolar hyperglycemic state). 1, 2 This recommendation exists because:

• Acute metabolic stress from the hyperglycemic crisis temporarily suppresses β-cell function, leading to falsely low C-peptide values that do not reflect the patient's true baseline insulin secretory capacity. 1
• Inflammatory mediators and counter-regulatory hormones (cortisol, catecholamines, glucagon) during the acute crisis further impair insulin secretion and can confound interpretation. 3
• Testing too early may incorrectly classify a patient as having severe insulin deficiency (type 1 diabetes) when they actually have preserved β-cell function (type 2 diabetes or other forms). 1, 2

Optimal Timing for C-Peptide Testing

Wait at least 2 weeks after complete resolution of the hyperglycemic emergency before measuring C-peptide for diabetes classification purposes. 1, 2 This allows:

• Full recovery of β-cell function from acute metabolic stress 1
• Normalization of counter-regulatory hormone levels 3
• Accurate assessment of endogenous insulin secretory capacity 1, 2

Testing Protocol After the Waiting Period

For Insulin-Treated Patients

Perform a random C-peptide test (with concurrent glucose) within 5 hours of eating, which can replace a formal stimulation test in the context of diabetes classification. 1, 2 Interpretation:

• C-peptide >600 pmol/L (>1.8 ng/mL): Indicates preserved β-cell function consistent with type 2 diabetes; the circumstances of testing do not matter at this level. 1, 2
• C-peptide <200 pmol/L (<0.6 ng/mL): Suggests type 1 diabetes or severe insulin deficiency. 1, 2
• C-peptide 200-600 pmol/L (0.6-1.8 ng/mL): Indeterminate; usually consistent with type 1 diabetes or MODY but may occur in insulin-treated type 2 diabetes, particularly in people with normal/low BMI or long disease duration. 1, 2

Important Testing Caveats

• If the result is <600 pmol/L and the concurrent glucose is <4 mmol/L (<70 mg/dL) or the person may have been fasting, repeat the test under better conditions. 1, 2
• Results showing very low levels (e.g., <80 pmol/L [<0.24 ng/mL]) do not need to be repeated, as they definitively indicate severe insulin deficiency. 1, 2
• C-peptide must be measured prior to insulin discontinuation to exclude severe insulin deficiency in insulin-treated patients. 1, 2

Special Considerations for Hypoglycemia Evaluation

If the clinical question is evaluating hypoglycemia (not diabetes classification), different rules apply:

• C-peptide should be measured during a documented hypoglycemic episode (glucose <55 mg/dL) along with insulin, proinsulin, β-hydroxybutyrate, and screening for sulfonylureas. 4, 5
• C-peptide ≥200 pmol/L (≥0.6 ng/mL) with insulin ≥3 mU/L (18 pmol/L) during hypoglycemia confirms inappropriate endogenous insulin secretion. 4
• The 2-week waiting period after hyperglycemic crisis still applies before attempting diagnostic hypoglycemia testing. 1, 2

Common Pitfalls to Avoid

• Testing too early (<2 weeks post-crisis) will yield unreliable results that may lead to misclassification and inappropriate treatment decisions. 1, 2
• Relying on fasting C-peptide alone in insulin-treated patients; a post-meal or random sample is more practical and equally informative for classification. 1, 2
• Ignoring concurrent glucose levels when interpreting C-peptide; low glucose at the time of sampling can suppress C-peptide and require repeat testing. 1, 2
• Using point-of-care glucose meters for diagnostic decisions; laboratory-measured plasma glucose is required for accurate interpretation. 5, 6